Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma

@article{Doolittle2013LongtermCF,
  title={Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma},
  author={Nancy D. Doolittle and Agnieszka Korfel and Meredith A Lubow and Elisabeth Schorb and Uwe Schlegel and Sabine Rogowski and R Fu and Edit D{\'o}sa and Gerald Illerhaus and Dale Kraemer and Leslie L. Muldoon and Pasquale Calabrese and Nancy A. Hedrick and Rose Marie Tyson and Kristoph Jahnke and Leeza M Maron and Robert W. Butler and Edward A. Neuwelt},
  journal={Neurology},
  year={2013},
  volume={81},
  pages={84 - 92}
}
Objective: To describe and correlate neurotoxicity indicators in long-term primary CNS lymphoma (PCNSL) survivors who were treated with high-dose methotrexate–based regimens with or without whole-brain radiotherapy (WBRT). Methods: Eighty PCNSL survivors from 4 treatment groups (1 with WBRT and 3 without WBRT) who were a minimum of 2 years after diagnosis and in complete remission underwent prospective neuropsychological, quality-of-life (QOL), and brain MRI evaluation. Clinical characteristics… Expand
Cognitive and neuroimaging outcomes of different treatment regimens for primary CNS lymphoma
TLDR
Survivors of primary CNS lymphoma treated with high-dose methotrexate-based chemotherapy and whole-brain radiotherapy had lower mean scores on tests of attention, executive function and motor speed, and had more white matter abnormalities on brain imaging in comparison to patients treated with higher dose regimens without whole- brain radiotherapy. Expand
Narrative review of primary central nervous system lymphoma: treatment-related neurotoxicity
TLDR
A comprehensive review of cognitive functioning in adult patients with PCNSL according to treatment modality is provided, and it includes articles reporting the results of standardized cognitive assessments. Expand
Beyond Survival - Cognition after Pediatric Brain Tumor
Background: Pediatric Brain Tumor (PBT) survivors suffer from cognitive sequelae, especially within the areas of cognitive tempo, attention, executive function and memory. The cognitive difficultiesExpand
Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ ALLG NHL 24 randomised controlled trial.
TLDR
Addition of rituximab to standard treatment in PCNSL patients did not impact neurocognitive functioning up to two years post-treatment, nor did treatment with 30Gy WBRT in patients ≤60 years-old. Expand
Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience
TLDR
The low-dose whole brain radiotherapy (WBRT) consolidation is associated with lower PCNSL relapses with only mild neurocognitive toxicity. Expand
Maintenance of multi-domain neurocognitive functions in patients with newly-diagnosed primary CNS lymphoma after primary cranial radiotherapy combined with methotrexate-based chemotherapy: A preliminary case-series study.
TLDR
Under the multidisciplinary treatment guidelines for treating patients with newly-diagnosed PCNSL, multi-domain NCF become stabilized and even improved after the course of conformal WBRT combined with or without MTX-based chemotherapy. Expand
Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review.
TLDR
Combined chemotherapy and radiotherapy seems to have a negative effect onHRQOL and cognition in patients with PCNSL, and information on its effect on cognition and HRQOL should be included in clinical decision-making. Expand
Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial
TLDR
The analysis of subjective QoL questionnaires and objective MMSE testing revealed thatQoL and cognition were conserved in the arm without early WBRT, and the results of G-PCNSL-SG1 challenge the place of W BRT in the primary therapy of PCNSL. Expand
Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy.
TLDR
The results demonstrated that the history of recurrence, number of cycles of MTX chemotherapy and age affected the development of leukoencephalopathy, and it is recommended that clinicians monitor the KPS score among outpatients with PCNSL. Expand
Long‐term survivors of primary central nervous system lymphoma
TLDR
A more severe clinical condition was found to be associated with increasing age and whole brain irradiation dose in long‐term survivors with PCNSL. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Cognitive status and quality of life after treatment for primary CNS lymphoma
TLDR
Combined modality treatment for primary CNS lymphoma is associated with cognitive impairment even in patients aged <60 years, and group differences in cognitive status and QOL could not be explained by anxiety, depression, or fatigue. Expand
Cognitive functions in survivors of primary central nervous system lymphoma
TLDR
Assessment of cognitive functioning and quality of life in PCNSL survivors treated either with WBRT ± MTX-based chemotherapy or chemotherapy alone revealed more pronounced cognitive impairment, particularly in the memory and attention/executive domains, among patients treated with W BRT ± chemotherapy. Expand
Neuropsychological outcome after chemotherapy for primary CNS lymphoma
TLDR
In patients with primary CNS lymphoma treated with a methotrexate (MTX)-based chemotherapy, no gross cognitive decline has to be expected as a long-term treatment effect. Expand
Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy
TLDR
Executive and Verbal Memory functions improved following induction chemotherapy, likely due to decreased tumor burden and discontinuation of corticosteroid and anticonvulsant medications and there was no significant cognitive decline up to 24 months post-chemotherapy and reduced-dose WBRT in this group of PCNSL patients. Expand
Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines.
  • D. Correa, L. Maron, +7 authors D. Schiff
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2007
TLDR
The incorporation of formal and systematic cognitive evaluations in PCNSL studies will improve the understanding of treatment-related neurotoxicity in this population of patients. Expand
Cognitive functions in primary CNS lymphoma after single or combined modality regimens.
TLDR
Comparisons according to treatment type after controlling for age and time since treatment completion showed that patients treated with HD-MTX alone had significantly higher scores on tests of selective attention and memory than patientstreated with the combined modality regimen. Expand
Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.
TLDR
BBBD-enhanced chemotherapy delivery, without subsequent radiotherapy, resulted in favorable survival and cognitive outcomes for patients with primary central nervous system lymphomas who had not previously undergone irradiation. Expand
Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma.
TLDR
It is concluded that chemotherapy alone is associated with a low risk of long-term neurotoxicity in primary central nervous system lymphoma and Methotrexate-induced white matter lesions detectable on magnetic resonance imaging are not inevitably associated with significant cognitive decline. Expand
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
TLDR
Although the addition of MGd to WBRT did not produce a significant overall improvement between treatment arms, MGd may improve memory and executive function and prolong time to neurocognitive and neurologic progression in patients with brain metastases from lung cancer. Expand
Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning.
  • S. Deprez, F. Amant, +8 authors S. Sunaert
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
Evidence of longitudinal changes in cognitive functioning and cerebral WM integrity after chemotherapy as well as an association between both are reported. Expand
...
1
2
3
4
5
...